“You’re the eighth rheumatologist that I’ve seen,” the patient told me. She ticked off her symptoms—pain, fatigue, and what she described as a sense of brain fog—which she’d lived with for years. Some doctors had no answers for her; others had said that she likely had fibromyalgia, a poorly understood pain-processing condition, and that they could do little to help. She began to cry, and I began to sweat.
My medical training had prepared me for seemingly everything—diagnosing heart attacks, treating life-threatening infections—but not for this kind of problem. I knew the technical definition of fibromyalgia, but my confidence in making the diagnosis correctly was exceedingly low: The disease can cause the symptoms my patient described but cannot be proven by lab or imaging studies. And even if fibromyalgia was the cause of her suffering, I had few concrete solutions to offer her.
Modern medicine is excellent at delivering treatments that precisely target the biological cause of a disease and produce clear, measurable improvement. The promise of such magic bullets shapes both doctors’ training and patients’ expectations. But for some of the most disabling conditions physicians treat today, no magic bullet exists, and doctors often struggle to identify what it is, exactly, that they’re shooting at.
Illnesses such as fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome (also known as myalgic encephalomyelitis, or ME/CFS) rarely reveal a single malfunctioning molecule or damaged organ. In such cases, the best medicine can offer is often a patchwork of modestly effective medications and nonpharmacological interventions such as cognitive behavioral therapy, exercise, and tai chi. The result is a quiet but profound mismatch between what modern medicine was built to do—identify targets and take aim at them—and the kinds of suffering many patients now bring into the exam room.
The concept of the “magic bullet” arrived at exactly the right moment. The German physician Paul Ehrlich first came up with the metaphor in the early 20th century, when infectious disease was the leading cause of death worldwide. Ehrlich imagined a medicine that could act like a perfectly aimed projectile, striking a disease-causing organism while leaving the rest of the body unharmed. Two years later, he demonstrated the idea experimentally, curing syphilis-infected rabbits with a chemical compound later named salvarsan, and within a few decades, the era of highly effective, modern antibiotics was under way. The success of the magic bullet helped establish a framework that shapes medicine to this day. Drug development focuses on discrete biological targets; medical training teaches physicians to think about disease in simplified terms, as a set of problems with clear mechanisms that can be addressed with specific interventions.
But not all diseases cooperate with this framework. Fibromyalgia, for instance, likely arises from abnormal pain processing in the nervous system rather than tissue damage; research studies have shown that, when exposed to the same stimuli, patients with fibromyalgia exhibit greater activation in brain regions associated with pain than healthy individuals. Many cases of IBS begin with an insult to the gut (such as an infection) that triggers persistent pain but over time also becomes a problem of the nervous system, which amplifies discomfort even in the absence of ongoing injury. “The brain is not the origin of the problem, but it is the organ that’s ultimately affected,” Braden Kuo, the chief of digestive and liver diseases at Columbia University’s Irving Medical Center, told me. Tests examining muscle response have shown that IBS patients experience pain when the rectum is stretched to levels that most people barely notice.
These tests, however, are not used in clinical practice, in part because of their high cost and the need for specialized expertise to interpret them. Efforts to identify biomarkers for these diseases in the blood have also been largely unsuccessful, and so biomarkers aren’t used to diagnose these conditions. According to Michael Kaplan, a rheumatologist at Mount Sinai whose research focuses on chronic pain, this poses a problem for patients trying to understand the root of their symptoms. “Patients come to the doctor expecting their suffering to be translated into the language of objectivity, but that’s just not possible for these conditions,” Kaplan told me. Instead, patients are left trying to understand how their symptoms can be so intense even though their lab and imaging results appear “normal.”
One reason that physicians aren’t pushing for more testing, according to several I spoke with, is the paucity of targeted therapies. When a doctor orders a test, they mostly want to know: Will the result change my management of this patient’s symptoms? For fibromyalgia and IBS, spending time and money on knowing exactly what’s wrong with a patient doesn’t help if the conversation still ends with “And there is not much we can do for you.” Physicians often dread these appointments not because they lack empathy, but because they have no magic bullet to offer the person sitting in front of them. “I say to patients, ‘If I had you on the perfect pharmacologic cocktail, it would only get us about one-third of the way to making you better,’” Kaplan said. Instead, managing chronic-pain syndromes in many cases requires long conversations about coping strategies, behavioral therapies, and lifestyle changes—precisely the kind of time-intensive care that modern medical systems are poorly designed to deliver.
For some conditions, a discrete biological target and its magic bullet may exist, even if no one has found it yet. For decades, obesity—a complex, multifactorial disease shaped by genetics, environment, and behavior—was regarded as a pharmacological lost cause. Then came GLP-1 agonists, which, though not a cure-all, have driven dramatic weight loss for millions of patients. Philip Mease, the director of rheumatology research at Swedish Health Services, in Seattle, told me he believes that a similar sea change could come for conditions such as fibromyalgia. The challenge, he argued, is clarifying what the disease is—and what it is not. Disorders such as long COVID share many overlapping symptoms with fibromyalgia, making misdiagnosis common. The result is a cascade of consequences: blurred disease boundaries, a grab bag of patients in clinical trials, stalled therapeutic progress.
Nortin Hadler, an emeritus professor of medicine at the University of North Carolina, told me that the issue extends far beyond subtle distinctions. In his view, doctors must be willing to confront a more fundamental divide: the difference between illness and disease. Patients with fibromyalgia, he argues, clearly experience illness—real, often-debilitating symptoms that disrupt daily life. But Hadler does not believe that fibromyalgia should be classified as a disease in the traditional biomedical sense, because medicine has yet to identify a discrete, demonstrable pathophysiological process underlying it. The problem, as he sees it, is that the medical system reflexively applies the label of “disease” and then looks for a targeted biological fix, creating expectations that may be misplaced. “The endless search for a cure may actually increase disability, because patients are distracted from learning how to live with their symptoms,” Hadler said.
Debates over conditions such as chronic fatigue syndrome and long COVID reveal how difficult it can be for modern medicine to balance the recognition of subjective—yet real—suffering with the quest for objective proof. The question of whether ME/CFS is a distinct biological disease or a psychosomatic problem has been contested for decades; the medical community’s interest in long COVID can depend, too, on whether it’s regarded as an illness or a disease. At a recent medical conference, I watched a speaker describe patients’ symptoms of brain fog to a relatively disengaged room of physicians—who suddenly sat at attention as he cited a study showing that, in people who died from COVID-19, viral genetic material persisted in multiple organs, including the brain, for up to 230 days after symptom onset. What changed in that moment was not the description of the patients’ suffering, but the possibility of a biological explanation linking subjective symptoms with an objective, see-for-yourself finding. Only then did the problem become legible to the room full of physicians.
But to meet the needs of patients with diseases such as fibromyalgia, IBS, chronic fatigue syndrome, and long COVID, medicine will need to loosen its reliance on the magic-bullet model. Not every illness will reveal a single molecular target, and not every treatment will come in the form of a pill or an injection. In many cases, the work of medicine will look less like marksmanship and more like navigation: helping patients experiment with therapies, manage symptoms, and rebuild a life shaped by chronic illness.
I found this to be the case with my patient. Over time, we used a combination of medications, exercise, and behavioral therapies to treat her symptoms, with some success. We never found one single, comprehensive solution, and at visits in which she described herself as really struggling, I wondered if I was providing any benefit to her care at all. But she kept coming back, and I kept trying. My medical training had taught me to search for the magic bullet—and to feel disappointed when I couldn’t find it. My patient showed me that medicine must move forward even without one.
The post Medicine Has a Magic-Bullet Problem appeared first on The Atlantic.
